Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Julio E Celis
  • ,
  • Pavel Gromov
  • ,
  • Irina Gromova
  • ,
  • José Manuel Alfonso Moreira, 2012 Institut for Lægemiddeldesign og Farmakologi, Danmark
  • Teresa Cabezón
  • ,
  • Noona Ambartsumian, Laboratory for Neuroplasticity, Danmark
  • Mariam Grigorian, Laboratory for Neuroplasticity, Danmark
  • Eugene Lukanidin
  • ,
  • Eivind Per thor Straten, SUND ph.d. skole, Danmark
  • Per Guldberg, Danmark
  • Jirina Bartkova
  • ,
  • Jiri Bartek, Afd. for Undervisning, Danmark
  • Jiri Lukas, 2012 Eksamenskontoret, Danmark
  • Claudia Lukas, Disease Biology, Danmark
  • Anne Lykkesfeldt, The Danish Centre for Translational Breast Cancer Research, Copenhagen, Danmark
  • Marja Jäättelä, Risø National Laboratory for Sustainable Energy, Danmark
  • Peter Roepstorff, Institut for Biokemi og Molekylær Biologi, Danmark
  • Lars Bolund
  • Torben Falck Ørntoft
  • Nils Brünner, The Danish Centre for Translational Breast Cancer Research, Copenhagen, Danmark
  • Jens Overgaard
  • Kerstin Sandelin
  • ,
  • Mogens Blichert-Toft
  • ,
  • Henning Mouridsen
  • ,
  • Fritz Rank, Diagnostiske Fag, Danmark
The application of state-of-the-art proteomics and functional genomics technologies to the study of cancer is rapidly shifting toward the analysis of clinically relevant samples derived from patients, as the ultimate aim of translational research is to bring basic discoveries closer to the bedside. Here we describe the essence of a long-term initiative undertaken by The Danish Centre for Translational Breast Cancer Research and currently underway for cancer biomarker discovery using fresh tissue biopsies and bio-fluids. The Centre is a virtual hub that brings together scientists working in various areas of basic cancer research such as cell cycle control, invasion and micro-environmental alterations, apoptosis, cell signaling, and immunology, with clinicians (oncologists, surgeons), pathologists, and epidemiologists, with the aim of understanding the molecular mechanisms underlying breast cancer progression and ultimately of improving patient survival and quality of life. The unifying concept behind our approach is the use of various experimental paradigms for the prospective analysis of clinically relevant samples obtained from the same patient, along with the systematic integration of the biological and clinical data.
TidsskriftMolecular and Cellular Proteomics
Sider (fra-til)369-77
Antal sider9
StatusUdgivet - jun. 2003

Se relationer på Aarhus Universitet Citationsformater

ID: 56680066